Skinvisible Announces Expansion With a New Scientific Skincare Company
“Premium Invisicare Powered Kintari(TM) Products Go to Market”
Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) today announced the forming of Kintari, a new wholly-owned subsidiary to market a premium line of scientifically formulated skincare products powered by the company’s patented Invisicare® technology. As part of the Company’s strategic focus on revenue generation and creating shareholder value, Kintari will be a direct sales company that will launch products initially in the United States and Canada.
The Kintari product portfolio consists of “Youth Renewed” (YR) anti-aging products to help fight the signs of aging. The Kintari YR product line will include a rejuvenating day cream and a renewing night cream. These products have been developed using proven anti-aging ingredients with scientific evidence of their effectiveness at reducing the look of fine lines and wrinkles resulting in youthful looking skin. These potent ingredients will be powered by our patented Invisicare technology, providing consumers with unique, effective products which cannot be duplicated. Additional products will be added to enhance this product line as the company grows and expands.
Skinvisible has selected the direct sales model for Kintari products as it enables the Company to reach consumers directly and effectively with superior products formulated with the benefits of Invisicare. Skinvisible’s founder and President, Mr. Terry Howlett, has substantial experience in the direct sales market having held senior management positions with a leading direct sales company in Dallas, Texas. Mr. Howlett also founded Presley Laboratories Inc., which marketed cosmetic and skin care products on a direct sales basis. Kintari’s expansion plans include the addition of experienced personnel from the direct sales industry to be announced shortly.
According to CosmeticsDesign.com, 44% of consumers will buy products that a family member, friend or colleague has recommended and 37% will pay more for that same beauty product if it is endorsed by someone they know personally. Kintari products have an exceptional fact-based scientific story which will lead to referrals from consumers highly satisfied with their results.
“Investment in our new subsidiary Kintari reflects Skinvisible’s ongoing commitment to maximize value for our shareholders,” said Mr. Terry Howlett, CEO of Skinvisible. “We have ambitious plans for many products. Our R&D pipeline consists of over thirty cosmeceutical and over-the-counter formulations which are available for Kintari to market. Our plan is to leverage the direct sales model to tell the Invisicare story which is the foundation of all our great products.” He added, “With the United States and Canadian markets planned for a fourth quarter launch, Kintari will start generating revenue in Q4.”
In line with Skinvisible’s direct sales strategy, Skinvisible Pharmaceuticals Inc. will continue to build its patent portfolio and its core business of R&D and licensing our prescription product line focused on dermatology conditions.
About Skinvisible Pharmaceuticals, Inc
Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Skinvisible receives a combination of license fees, and ongoing royalties for its licensed product formulations. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. www.skinvisible.com www.invisicare.com.
Forward-Looking Statements: This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10k for the quarter ending June 30, 2014).
Contact:
John Pentony
Investor Relations
Phone: 972-292-8930
Email: [email protected]
John Pentony now represents Skinvisible Pharmaceuticals, Inc. as its investor relations coordinator internally. In the past John Pentony’s company was hired for the distribution of news and blogs about Skinvisible. John Pentony and any family member or associated companies do not hold shares, warrants or other positions in Skinvisible stock. In years past John Pentony’s company (Pentony Enterprise LLC / “PE”) has received a total of eight thousand in cash payments. In 2009 PE was compensated 500k shares of restricted stock. John Pentony has signed a contract to as investor relations for Skinvisible, and will be paid up to eleven thousand dollars during the next twelve months should the contract go for twelve months as expected.